These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

206 related articles for article (PubMed ID: 36482326)

  • 41. Evaluation of the efficacy and safety of intravenous remdesivir in adult patients with severe COVID-19: study protocol for a phase 3 randomized, double-blind, placebo-controlled, multicentre trial.
    Wang Y; Zhou F; Zhang D; Zhao J; Du R; Hu Y; Cheng Z; Gao L; Jin Y; Luo G; Fu S; Lu Q; Du G; Wang K; Lu Y; Fan G; Zhang Y; Liu Y; Ruan S; Liu W; Jaki T; Hayden FG; Horby PW; Cao B; Wang C
    Trials; 2020 May; 21(1):422. PubMed ID: 32448345
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Double-blind, randomized, controlled, trial to assess the efficacy of allogenic mesenchymal stromal cells in patients with acute respiratory distress syndrome due to COVID-19 (COVID-AT): A structured summary of a study protocol for a randomised controlled trial.
    Payares-Herrera C; Martínez-Muñoz ME; Vallhonrat IL; de Molina RM; Torres MP; Trisan A; de Diego IS; Alonso R; Zafra R; Donaire T; Sánchez R; Rubio JJ; Duarte Palomino RF; Solá CA
    Trials; 2021 Jan; 22(1):9. PubMed ID: 33407777
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Effect of Ivermectin 600 μg/kg for 6 days vs Placebo on Time to Sustained Recovery in Outpatients with Mild to Moderate COVID-19: A Randomized Clinical Trial.
    Naggie S; Boulware DR; Lindsell CJ; Stewart TG; Lim SC; Cohen J; Kavtaradze D; Amon AP; Gabriel A; Gentile N; Felker GM; Rothman RL; Jayaweera D; McCarthy MW; Sulkowski M; Wilson S; DeLong A; Remaly A; Wilder R; Collins S; Dunsmore SE; Adam SJ; Thicklin F; Hanna GJ; Ginde AA; Castro M; McTigue K; Shenkman E; Hernandez AF;
    medRxiv; 2022 Dec; ():. PubMed ID: 36561174
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Ivermectin for Treatment of Mild-to-Moderate COVID-19 in the Outpatient Setting: A Decentralized, Placebo-controlled, Randomized, Platform Clinical Trial.
    ; Naggie S
    medRxiv; 2022 Aug; ():. PubMed ID: 35982669
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Effect of Bamlanivimab as Monotherapy or in Combination With Etesevimab on Viral Load in Patients With Mild to Moderate COVID-19: A Randomized Clinical Trial.
    Gottlieb RL; Nirula A; Chen P; Boscia J; Heller B; Morris J; Huhn G; Cardona J; Mocherla B; Stosor V; Shawa I; Kumar P; Adams AC; Van Naarden J; Custer KL; Durante M; Oakley G; Schade AE; Holzer TR; Ebert PJ; Higgs RE; Kallewaard NL; Sabo J; Patel DR; Klekotka P; Shen L; Skovronsky DM
    JAMA; 2021 Feb; 325(7):632-644. PubMed ID: 33475701
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Safety, tolerability, and immunogenicity of an inactivated SARS-CoV-2 vaccine in healthy adults aged 18-59 years: a randomised, double-blind, placebo-controlled, phase 1/2 clinical trial.
    Zhang Y; Zeng G; Pan H; Li C; Hu Y; Chu K; Han W; Chen Z; Tang R; Yin W; Chen X; Hu Y; Liu X; Jiang C; Li J; Yang M; Song Y; Wang X; Gao Q; Zhu F
    Lancet Infect Dis; 2021 Feb; 21(2):181-192. PubMed ID: 33217362
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Efficacy of Niclosamide vs Placebo in SARS-CoV-2 Respiratory Viral Clearance, Viral Shedding, and Duration of Symptoms Among Patients With Mild to Moderate COVID-19: A Phase 2 Randomized Clinical Trial.
    Cairns DM; Dulko D; Griffiths JK; Golan Y; Cohen T; Trinquart L; Price LL; Beaulac KR; Selker HP
    JAMA Netw Open; 2022 Feb; 5(2):e2144942. PubMed ID: 35138402
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Hydroxychloroquine in the treatment of adult patients with Covid-19 infection in a primary care setting (LIBERTY): A structured summary of a study protocol for a randomised controlled trial.
    Vainio PJ; Hietasalo P; Koivisto AL; Kääriäinen S; Turunen J; Virtala M; Vuorinen J; Scheinin M
    Trials; 2021 Jan; 22(1):44. PubMed ID: 33430933
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Ivermectin in combination with doxycycline for treating COVID-19 symptoms: a randomized trial.
    Mahmud R; Rahman MM; Alam I; Ahmed KGU; Kabir AKMH; Sayeed SKJB; Rassel MA; Monayem FB; Islam MS; Islam MM; Barshan AD; Hoque MM; Mallik MU; Yusuf MA; Hossain MZ
    J Int Med Res; 2021 May; 49(5):3000605211013550. PubMed ID: 33983065
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Use of ivermectin in the treatment of Covid-19: A pilot trial.
    Pott-Junior H; Paoliello MMB; Miguel AQC; da Cunha AF; de Melo Freire CC; Neves FF; da Silva de Avó LR; Roscani MG; Dos Santos SS; Chachá SGF
    Toxicol Rep; 2021; 8():505-510. PubMed ID: 33723507
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Use of an antiviral mouthwash as a barrier measure in the SARS-CoV-2 transmission in adults with asymptomatic to mild COVID-19: a multicentre, randomized, double-blind controlled trial.
    Carrouel F; Valette M; Gadea E; Esparcieux A; Illes G; Langlois ME; Perrier H; Dussart C; Tramini P; Ribaud M; Bouscambert-Duchamp M; Bourgeois D
    Clin Microbiol Infect; 2021 Oct; 27(10):1494-1501. PubMed ID: 34044151
    [TBL] [Abstract][Full Text] [Related]  

  • 52. A Randomized Placebo-Controlled Trial of Leronlimab in Mild-To-Moderate COVID-19.
    Seethamraju H; Yang OO; Loftus R; Ogbuagu O; Sammartino D; Mansour A; Sacha JB; Ojha S; Hansen SG; Arman AC; Lalezari JP
    Clin Ther; 2024 Sep; ():. PubMed ID: 39353749
    [TBL] [Abstract][Full Text] [Related]  

  • 53. The effect of ivermectin on the viral load and culture viability in early treatment of nonhospitalized patients with mild COVID-19 - a double-blind, randomized placebo-controlled trial.
    Biber A; Harmelin G; Lev D; Ram L; Shaham A; Nemet I; Kliker L; Erster O; Mandelboim M; Schwartz E
    Int J Infect Dis; 2022 Sep; 122():733-740. PubMed ID: 35811080
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Efficacy and Safety of Hydroxychloroquine vs Placebo for Pre-exposure SARS-CoV-2 Prophylaxis Among Health Care Workers: A Randomized Clinical Trial.
    Abella BS; Jolkovsky EL; Biney BT; Uspal JE; Hyman MC; Frank I; Hensley SE; Gill S; Vogl DT; Maillard I; Babushok DV; Huang AC; Nasta SD; Walsh JC; Wiletyo EP; Gimotty PA; Milone MC; Amaravadi RK;
    JAMA Intern Med; 2021 Feb; 181(2):195-202. PubMed ID: 33001138
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Evaluating the efficacy and safety of human anti-SARS-CoV-2 convalescent plasma in severely ill adults with COVID-19: A structured summary of a study protocol for a randomized controlled trial.
    Eckhardt CM; Cummings MJ; Rajagopalan KN; Borden S; Bitan ZC; Wolf A; Kantor A; Briese T; Meyer BJ; Jacobson SD; Scotto D; Mishra N; Philip NM; Stotler BA; Schwartz J; Shaz B; Spitalnik SL; Eisenberger A; Hod EA; Justman J; Cheung K; Lipkin WI; O'Donnell MR
    Trials; 2020 Jun; 21(1):499. PubMed ID: 32513308
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Norwegian Coronavirus Disease 2019 (NO COVID-19) Pragmatic Open label Study to assess early use of hydroxychloroquine sulphate in moderately severe hospitalised patients with coronavirus disease 2019: A structured summary of a study protocol for a randomised controlled trial.
    Lyngbakken MN; Berdal JE; Eskesen A; Kvale D; Olsen IC; Rangberg A; Jonassen CM; Omland T; Røsjø H; Dalgard O
    Trials; 2020 Jun; 21(1):485. PubMed ID: 32503662
    [TBL] [Abstract][Full Text] [Related]  

  • 57. A Phase I/II Clinical Trial to evaluate the efficacy of baricitinib to prevent respiratory insufficiency progression in onco-hematological patients affected with COVID19: A structured summary of a study protocol for a randomised controlled trial.
    Moreno-González G; Mussetti A; Albasanz-Puig A; Salvador I; Sureda A; Gudiol C; Salazar R; Marin M; Garcia M; Navarro V; de la Haba Vaca I; Coma E; Sanz-Linares G; Dura X; Fontanals S; Serrano G; Cruz C; Mañez R
    Trials; 2021 Feb; 22(1):116. PubMed ID: 33546739
    [TBL] [Abstract][Full Text] [Related]  

  • 58. A double blinded placebo controlled comparative clinical trial to evaluate the effectiveness of Siddha medicines, Kaba Sura Kudineer (KSK) & Nilavembu Kudineer (NVK) along with standard Allopathy treatment in the management of symptomatic COVID 19 patients - a structured summary of a study protocol for a randomized controlled trial.
    Srivastava A; Rengaraju M; Srivastava S; Narayan V; Gupta V; Upadhayay R
    Trials; 2021 Feb; 22(1):130. PubMed ID: 33573696
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Safety and immunogenicity of the SARS-CoV-2 ARCoV mRNA vaccine in Chinese adults: a randomised, double-blind, placebo-controlled, phase 1 trial.
    Chen GL; Li XF; Dai XH; Li N; Cheng ML; Huang Z; Shen J; Ge YH; Shen ZW; Deng YQ; Yang SY; Zhao H; Zhang NN; Zhang YF; Wei L; Wu KQ; Zhu MF; Peng CG; Jiang Q; Cao SC; Li YH; Zhao DH; Wu XH; Ni L; Shen HH; Dong C; Ying B; Sheng GP; Qin CF; Gao HN; Li LJ
    Lancet Microbe; 2022 Mar; 3(3):e193-e202. PubMed ID: 35098177
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Safety and efficacy of antiviral combination therapy in symptomatic patients of Covid-19 infection - a randomised controlled trial (SEV-COVID Trial): A structured summary of a study protocol for a randomized controlled trial.
    Panda PK; Bandyopadhyay A; Singh BC; Moirangthem B; Chikara G; Saha S; Bahurupi YA
    Trials; 2020 Oct; 21(1):866. PubMed ID: 33081849
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 11.